Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more

Urgent action needed to avoid widespread shortage of in-vitro diagnostic tests

In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.

Read more

Selected EMA news

January 2025New medicines recommended for approval
Rytelo (imetelstat sodium) - orphan
Treatment of anemia (low levels of red blood cells)
Zefylti (filgrastim) – biosimilar
Treatment of neutropenia (low level of white blood cells) in patients having chemotherapy or a bone marrow transplant
New…

Read more

Meeting Program

All times are in GMT-3, local time in Brazil.

Read more

GoCART coalition activities (CARTs and cellular therapies)

GoCART Clinical Case Discussion Series for Physicians - 4th edition
Panel: Dr. Sara Ghorashian, Dr. Peter Bader and Dr. Franco Locatelli along with moderator Dr.

Read more

Second EHA-SAH tutorial in Argentina, another success

Hematologists from South America and mainland US gathered in Argentina on September 14-15 for brain-stretching exercises on the topics of lymphoid malignancies and plasma cell dyscrasias.

Read more

EHA-KCS Hematology Tutorial on Lymphoma and Multiple Myeloma

Dates: March 14-16, 2019
Location: Almaty, Kazakhstan
Chairs: G Gaidano, D Kaidarova
Co-chairs: S Gabbasova, B Afanasyev 

This meeting will be held in English and offer a simultaneous translation to Russian.

Read more